article thumbnail

STAT+: Pharmalittle: We’re reading about Trump’s latest tariff threat, a Merck deal, and lots more

STAT

Details on pharmaceutical tariffs “will come at the end of the month,” U.S. The planned tariffs would deal a long-awaited blow to pharmaceutical companies, many of which have pushed back and warned that the levies could drive up costs, deter investments in the U.S., billion in 2021. Merck

article thumbnail

STAT+: Pharmalittle: We’re reading about a key Merck drug trial, cheap Wegovy in China, and more

STAT

patent expires in 2028. Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, overall industry efforts remain limited and patient access continues to suffer as a result , STAT writes, citing a new analysis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RFK Jr axes vaccine advisory committee members

Pharmaceutical Technology

Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028, RFK Jr wrote. He noted that these conflicts of interest continue to the current day, with ACIP members receiving substantial funding from pharmaceutical companies.

article thumbnail

Europe’s pharmaceutical packaging market to value over $35bn by 2028

European Pharmaceutical Review

Europe’s pharmaceutical packaging and labelling market is projected to reach $35.78 billion in 2028, according to a report by Arizton. billion in 2022, the pharmaceutical packaging and labelling market in Europe is expected to expand at a compound annual growth rate (CAGR) of 4.78 percent up to 2028. percent in 2022.

article thumbnail

Pharmaceutical excipients market to witness expansion

European Pharmaceutical Review

A report published by MarketsandMarkets has estimated that the pharmaceutical excipients market will value $14.9 billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. This is compared to the expected revenue for the market in 2023 reaching $10.7

article thumbnail

STAT+: Pharmalittle: We’re reading about Sarepta’s demand to censor a video, Roche fast-tracking an obesity pill, and more

STAT

Thomas Schinecker, chief executive of the pharmaceutical company, said its first obesity drugs would come to market “significantly faster than people are expecting,” potentially by 2028. The treatments, acquired in a $3.1 reduction in weight compared with a placebo after four weeks.

article thumbnail

Growing pains: how the pharmaceutical industry can hire and retain talent during industry boom

pharmaphorum

Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. Paired with the current US pharmaceutical job vacancy rate of around 8%, companies will need to pivot to fill the incredible labour needs.